reference/12539922

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12539922

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase II\|Journal Article
endingPage	1071
issn	0923-7534
issueIdentifier	7
pageRange	1067-1071
publicationName	Annals of oncology : official journal of the European Society for Medical Oncology
startingPage	1067
bibliographicCitation	Sharma S, Kemeny N, Kelsen DP, Ilson D, O'Reilly E, Zaknoen S, Baum C, Statkevich P, Hollywood E, Zhu Y, Saltz LB. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol. 2002 Jul;13(7):1067–71. doi: 10.1093/annonc/mdf173. PMID: 12176785.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_554be607e546793c354f3b34dbb7d8ea http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_be8cd6b8cd94fd12b291f140604d2ba7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0ccc1013fcd3b92cbaf202c787ef0238 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cb21a24e1495a001421a6638d091068a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bd30ac21dda02da2009557dacaf7f54a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_90019601960c59075694bc8c61e2e87f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_63a821287c1f3f485c39cb9b2a53810c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cd171ca5b3074625d248005f39c2e04b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ce372d521a083698c6ed3e14f991cd30 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ebd6246515f9a0234192f82b48146b65 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4b3390525afe0b50fdc3179ec2a8af01
date	200207
identifier	https://doi.org/10.1093/annonc/mdf173 https://pubmed.ncbi.nlm.nih.gov/12176785
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1846 https://portal.issn.org/resource/ISSN/0923-7534
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan
discusses	http://id.nlm.nih.gov/mesh/M0007520 http://id.nlm.nih.gov/mesh/M0008631 http://id.nlm.nih.gov/mesh/M0297075 http://id.nlm.nih.gov/mesh/M0016885 http://id.nlm.nih.gov/mesh/M0018233
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D019008 http://id.nlm.nih.gov/mesh/D010880Q000008 http://id.nlm.nih.gov/mesh/D005472Q000008 http://id.nlm.nih.gov/mesh/D004791Q000008 http://id.nlm.nih.gov/mesh/D015179Q000188 http://id.nlm.nih.gov/mesh/D011725Q000008
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D009367 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D008175Q000556 http://id.nlm.nih.gov/mesh/D000284 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D005500 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D015179Q000473 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D001707 http://id.nlm.nih.gov/mesh/D008113Q000556 http://id.nlm.nih.gov/mesh/D004351
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7811 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60838 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9672 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444108 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148195 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7947 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3385 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID588

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127952853 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128299169 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127719861 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129430288 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127735655

Total number of triples: 78.